Singapore, May 9, 2008: Siemens Healthcare and Laboratory Corporation of America Holdings (LabCorp) have entered a non-exclusive agreement to discuss future possibilities to co-develop new clinical diagnostic tests in the areas of companion diagnostics, metabolic syndrome, oncology and diabetes. Under the agreement, initial discussions will focus on developing new tests that could make the biggest impact to patient care.

 

Siemens is a key player in the diagnostic industry with the broadest range of products and services used for diagnosing medical conditions and monitoring patient therapy; LabCorp is a reference laboratory successfully serving more than 220,000 clients in America. Together, the companies are well positioned to co-develop and introduce new diagnostic tests that may advance patient care through early detection and proper monitoring of disease.

 

"This agreement establishes a framework that gives both companies the opportunity to offer new diagnostic tests to laboratories, physicians and their patients more quickly and effectively than either could do alone. Advancing health care for patients is an important commitment that we can reach through strategic relationships such as this," said Mr Dave Hickey, senior vice president strategic planning and business development, Siemens Healthcare Diagnostics.

 

"LabCorp is excited about this strategic collaboration and its impact on our companion diagnostics efforts. Alliances, such as this between developers and providers of new tests, are critical in translating emerging biomarkers from research into clinical practice," said Dr Myla P. Lai-Goldman, executive vice president, chief scientific officer and medical director for LabCorp."